ANNUAL REPORT - Pevion Biotech AG

More documents

Recommendations

Info

INDEX LETTER FROM THE CEO ......................................................................................3 HIGHLIGHTS IN 2005 ............................................................................................4 COMPANY PROFILE .............................................................................................5 PRODUCT DEVELOPMENT..................................................................................6 LEAD PROJECTS ...................................................................................................9 Pevion Biotech_Annual Report2005_01_01_04_004 2/13
LETTER FROM THE CEO 2005 ANNUAL REPORT Dear Shareholder Vaccines are one of the fastest growing market segments in the healthcare industry. Especially therapeutic and cancer vaccines contribute to this market growth. Currently, there are anti-cancer products based on passive immunization with antibodies on the market. However, this type of vaccines requires an expensive production process that leads to high prices on the market. In the future, these treatments will be joined by more economical vaccines based on tumor antigens. Pevion Biotech’s validated technology and development process according to industrial standards enabled us to start the product development of cancer vaccines in early 2005. Due to an accelerated development process Pevion Biotech was able to reformulate a very promising breast cancer antigen according to GMP standards in a short period of time. The product candidate, which is developed in cooperation with Bio Life Science in Vienna, is scheduled to enter the phase I clinical study in Q2 2006. In 2005 Pevion Biotech also reached important milestones in the field of prevention and therapy of infectious diseases. The malaria vaccine candidate entered clinical phase II, and in addition the HCV vaccine candidate is ready to enter clinical phase I in Q3 2006. In 2005 the company followed its aggressive patent strategy and submitted 2 technology and product patents respectively. With regard to the life cycle management of the virosome technology, Pevion Biotech established a new process for the production of fully functional lyophilized virosomes. This process improved the stability characteristics of virosome vaccines and furthermore boosted doctor compliance. Lyophilized virosome products can be stored even at room temperature, overcoming common stability issues known for most vaccines. After reconstitution, the lyophilized virosome formulated vaccine is still fully active. The lyophilization process will bring us one step further towards the creation of high potential and premium virosome vaccines. As a matter of fact, Pevion Biotech’s key strengths predominantly lie in market-approved virosome technology, which benefits from strong patent protection. The industrial experience and the broad applicability of this carrier enable an accelerated product development process. Together with their excellent safety profile, which also includes broad market experience with children, the elderly and immune-suppressed persons, the resulting vaccines will be a competitive advantage in the market. In 2006, our company will further strengthen its product pipeline and will be well positioned on the way to create considerable added value in 2006. Sincerely, Peter Klein CEO Pevion Biotech AG Pevion Biotech_Annual Report2005_01_01_04_004 3/13
Page 1: 2005 ANNUAL REPORT Pevion Biotech L
Page 5 and 6: COMPANY PROFILE 2005 ANNUAL REPORT
Page 7 and 8: THE VIROSOME TECHNOLOGY 2005 ANNUAL
Page 9 and 10: LEAD PROJECTS 2005 ANNUAL REPORT De
Page 11 and 12: This project was supported by the C
Page 13: Pevion Biotech Ltd. Rehhagstrasse 7

ANNUAL REPORT - Pevion Biotech AG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?